US child, teen obesity rates reach record high while adult trends appear to slow: CDC

CDC NHANES data (Aug 2021–Aug 2023) show 40.3% of U.S. adults aged 20+ are obese (9.7% severe) versus 42.4% in 2017–18, suggesting a possible recent plateau, while U.S. children/teens (ages 2–19) hit a record 21.1% obesity with 7% severe and ~23% for ages 12–19. Experts note the adult plateau may reflect public-health efforts and growing use of GLP-1 therapies (e.g., Ozempic, Wegovy, Mounjaro), but sampling caveats mean trends require more data; the persistent rise in youth obesity implies rising long-term demand for pediatric and metabolic treatments and potential healthcare-cost pressure over time.

Analysis

Market structure: The immediate winners are branded GLP‑1 makers (Eli Lilly LLY, Novo Nordisk NVO) plus biologics CMOs (Catalent CTLT, Lonza LZAGY) and specialty pharmacy/PBM channels (CVS, WBA, CVS:CVS Caremark). Bariatric device/robotic surgery names (Intuitive ISRG, Medtronic MDT) are mixed — potential tailwind from increased treatment volume for adolescents but downside if drugs reduce surgical demand over 3–5 years. Supply–demand is skewed to pharma: demand growth likely outstrips manufacturing capacity near term (6–18 months), creating pricing power and potential shortages that favor CMOs.

Risk assessment: Key tail risks are regulatory price controls/Medicare coverage decisions (6–12 month horizon), high‑profile adverse events or off‑label use litigation, and biologics manufacturing bottlenecks that could cap growth. In the immediate term (days–weeks) expect headline-driven volatility; short term (months) earnings and capacity announcements will reprice winners; long term (3–5 years) generic/biosimilar entry and policy responses could compress margins. Hidden dependencies: reimbursement elasticity, pediatric approvals, and chronic‑treatment adherence (rebound weight regain) — any of which could materially change demand curves.

Trade implications: Construct modest, risk‑managed exposure: buy 9–12 month call spreads on LLY (ticker LLY) sized 1–2% of portfolio; add 1% position in NVO via LEAP call spreads to hedge FX. Add 1–1.5% exposure to CMOs (CTLT or LZAGY) for manufacturing upside; implement a pair trade long LLY / short McDonald’s (MCD) via 3–6 month 5% OTM puts on MCD to express consumer‑spend shift. Consider buying 6–12 month protection (puts) on large insurers (UNH) with 0.5–1% size to hedge potential near‑term reimbursement shocks. Enter on any >5% pullback or around Q2 earnings; target 20–35% upside within 12–18 months, trim at those levels.

Key Decisions for Investors

• Establish a 1–2% portfolio position in Eli Lilly (LLY) via 9–12 month call spread (buy 20–30% ITM calls, sell 50% OTM calls) to capture GLP‑1 revenue upside while capping premium outlay; enter on a ≤5% pullback or ahead of Q2 earnings, target +25% in 12–18 months.
• Add a 1% LEAP call spread on Novo Nordisk (NVO) for geographic diversification (Danish krona exposure); size smaller due to FX and regulatory risk, hold 12–24 months and reassess after US reimbursement guidance.
• Allocate 1–1.5% to contract manufacturers (Catalent CTLT or Lonza LZAGY) via outright equity or long‑dated calls to play capacity tightness; plan to add on news of capacity expansion agreements and take profits at +30–40%.
• Implement a pair trade: long LLY (as above) and short McDonald's (MCD) via 3–6 month 5% OTM puts (size 0.5–1%) to express demand shift away from calorie‑dense fast food; close on signs of GLP‑1 insurance coverage rollouts or after 20% move in either leg.
• Buy 6–12 month puts (0.5–1% portfolio) on UnitedHealth (UNH) or similar insurer to hedge reimbursement risk around potential Medicare/Medicaid policy changes; unwind if CMS signals favorable coverage within 6 months.